Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro
Jang, M.; Park, Y.-I.; Park, R.; Cha, Y.-E.; Namkoong, S.; Lee, J. I.; Park, J.
Show abstract
COVID-19 has caused over 900,000 deaths worldwide as of September 2020, and effective medicines are urgently needed. Lopinavir was identified as an inhibitor of the HIV protease, and a lopinavir-ritonavir combination therapy was reported to be beneficial for the treatment of SARS and MERS. However, recent clinical tests could not prove that lopinavir-ritonavir therapy was an effective treatment for COVID-19. In this report, we examined the effect of lopinavir and ritonavir to the activity of the purified main protease (Mpro) protein of SARS- CoV-2, the causative virus of COVID-19. Unexpectedly, lopinavir and ritonavir did not inhibit Mpro activity. These results will aid the drug candidate selection for ongoing and future COVID-19 clinical trials.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system 96%
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin 94%
- Treatment Profiles And Clinical Outcomes Of COVID-19 Patients At Private Hospital In Jakarta 94%
Similar papers in this journal
- 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro 96%
- A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism 93%
- Computational analysis of the adaptability of H9N2 avian influenza virus: A comparative docking simulation study 93%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo 96%
- Discovery of Potent Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L 95%
- Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.